tetano
Editor, Senior Moderator
Vaccine
. 2024 Apr 18:S0264-410X(24)00452-3.
doi: 10.1016/j.vaccine.2024.04.038. Online ahead of print. Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken
Fiona Ingrao[SUP] 1 [/SUP], Eva Ngabirano[SUP] 2 [/SUP], Fabienne Rauw[SUP] 2 [/SUP], Gwenaëlle Dauphin[SUP] 3 [/SUP], Bénédicte Lambrecht[SUP] 2 [/SUP]
Affiliations
The application of recombinant herpesvirus of turkey, expressing the H9 hemagglutinin gene from low pathogenic avian influenza virus (LPAIV) H9N2 and the avian orthoavulavirus-1 (AOAV-1) (commonly known as Newcastle Disease virus (NDV)) fusion protein (F) as an rHVT-H9-F vaccine, is an alternative to currently used classical vaccines. This study investigated H9- and ND-specific humoral and mucosal responses, H9-specific cell-mediated immunity, and protection conferred by the rHVT-H9-F vaccine in specific pathogen-free (SPF) chickens. Vaccination elicited systemic NDV F- and AIV H9-specific antibody response but also local antibodies in eye wash fluid and oropharyngeal swabs. The ex vivo H9-specific stimulation of splenic and pulmonary T cells in the vaccinated group demonstrated the ability of vaccination to induce systemic and local cellular responses. The clinical protection against a challenge using a LPAIV H9N2 strain of the G1 lineage isolated in Morocco in 2016 was associated with a shorter duration of shedding along with reduced viral genome load in the upper respiratory tract and reduced cloacal shedding compared to unvaccinated controls.
Keywords: Avian influenza; Cell-mediated immunity; Chicken; Herpesvirus of turkey; Mucosal immunity; Vaccine.
. 2024 Apr 18:S0264-410X(24)00452-3.
doi: 10.1016/j.vaccine.2024.04.038. Online ahead of print. Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken
Fiona Ingrao[SUP] 1 [/SUP], Eva Ngabirano[SUP] 2 [/SUP], Fabienne Rauw[SUP] 2 [/SUP], Gwenaëlle Dauphin[SUP] 3 [/SUP], Bénédicte Lambrecht[SUP] 2 [/SUP]
Affiliations
- PMID: 38641498
- DOI: 10.1016/j.vaccine.2024.04.038
The application of recombinant herpesvirus of turkey, expressing the H9 hemagglutinin gene from low pathogenic avian influenza virus (LPAIV) H9N2 and the avian orthoavulavirus-1 (AOAV-1) (commonly known as Newcastle Disease virus (NDV)) fusion protein (F) as an rHVT-H9-F vaccine, is an alternative to currently used classical vaccines. This study investigated H9- and ND-specific humoral and mucosal responses, H9-specific cell-mediated immunity, and protection conferred by the rHVT-H9-F vaccine in specific pathogen-free (SPF) chickens. Vaccination elicited systemic NDV F- and AIV H9-specific antibody response but also local antibodies in eye wash fluid and oropharyngeal swabs. The ex vivo H9-specific stimulation of splenic and pulmonary T cells in the vaccinated group demonstrated the ability of vaccination to induce systemic and local cellular responses. The clinical protection against a challenge using a LPAIV H9N2 strain of the G1 lineage isolated in Morocco in 2016 was associated with a shorter duration of shedding along with reduced viral genome load in the upper respiratory tract and reduced cloacal shedding compared to unvaccinated controls.
Keywords: Avian influenza; Cell-mediated immunity; Chicken; Herpesvirus of turkey; Mucosal immunity; Vaccine.